Willow review: costs and what to check
As of Nov 4, 2026, Willow’s official website says “Willow treatment plans start at $299 per month” and include medication, a medical evaluation, unlimited doctor access, 24/7 online support and free shipping. It lists semaglutide tablets and injections and tirzepatide tablets and injections. It does not publish a price for each medication or plan length, so the starting price is not a confirmed quote for every formulation or dose. The site says Willow does not require insurance and lists the plans as FSA and HSA eligible.
This is a desk review of public information, not a treatment trial. We have not enrolled, tested medication or verified patient outcomes. ClearMetabolic is an approved affiliate and may earn a commission from purchases through our link. We have not assigned a score.
What the starting price leaves unanswered
Before paying, request the exact medication and formulation, your total initial payment, renewal charge, cancellation deadline and refund policy if treatment is declined. We have not independently verified these transaction-specific terms. Do not assume the starting price applies to tirzepatide or every dose.
Compounded products and advertising history
Willow’s website states that compounded medications “are not approved by the FDA,” that the FDA does not review them for safety, effectiveness or quality, and that they “are not brand-equivalent.” It says state-licensed compounding pharmacies prepare them and Willow is not the pharmacy. Results from trials of approved medicines do not establish equivalent outcomes for compounded products. The FDA said in February 2026 that companies cannot claim compounded products are the same as FDA-approved drugs.
Tablet versions deserve extra caution. Willow lists compounded semaglutide and tirzepatide tablets. These are not the same products as the FDA-approved Wegovy pill, and FDA has not approved any tirzepatide tablet. Ask the prescriber what evidence supports the specific product.
In a December 4, 2025 announcement, BBB National Programs said its National Advertising Division (NAD) found Willow “did not provide evidence to substantiate its express claims regarding health, weight loss” and related claims. The only studies Willow cited were of Novo Nordisk’s FDA-approved semaglutide products. NAD said it would refer Willow to the appropriate regulatory authorities, including state attorneys general, after Willow did not commit to comply.
There is a subsequent update: in its July 24, 2026 announcement, BBB National Programs reported that Willow had voluntarily discontinued the challenged claims for its compounded semaglutide products during a reopened inquiry in a challenge brought by Novo Nordisk. That is an advertising-case update, not approval of the medicines or proof of their effectiveness.
Availability
Willow’s website says “Prescription product availability varies by state” and does not name the states it serves. The affiliate terms supplied to ClearMetabolic restrict promotion in several states. Those terms do not tell you where Willow can treat patients, so confirm your state during signup.
Our assessment
Willow is worth comparing if you want online evaluation, but obtain a treatment-specific quote and understand the formulation before committing. Affiliate approval does not establish medical suitability. Ask the prescribing clinician about approved alternatives and the evidence for the proposed treatment.
Affiliate link. Prescription and eligibility decisions belong to the clinician.
What we checked
This AI-assisted public-source desk check reviewed Willow’s website, BBB National Programs’ December 2025 and July 2026 NAD announcements and the FDA’s February 2026 statement on compounded GLP-1 marketing on November 4, 2026. We did not complete signup, pay for treatment, test delivery or support, or independently verify clinician and pharmacy credentials. Prices and policies change, so confirm them with the provider or your prescriber before you act.